Pfizer (PFE) Total Non-Current Liabilities (2009 - 2026)

Pfizer (PFE) has 18 years of Total Non-Current Liabilities data on file, last reported at $113.5 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $113.5 billion, up 1.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.5 billion (up 1.65% YoY), and the FY2025 annual result was $5.7 billion, down 7.57% from the prior year.
• Total Non-Current Liabilities improved to $113.5 billion in Q1 2026 per PFE's latest filing, from $5.7 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $121.0 billion in Q3 2024 and troughed at $5.7 billion in Q4 2025.
• A 5-year average of $77.6 billion and a median of $102.0 billion in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 537.15% in 2023, then fell 15.69% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $6.0 billion in 2022, then climbed by 0.03% to $6.0 billion in 2023, then climbed by 3.45% to $6.2 billion in 2024, then dropped by 7.57% to $5.7 billion in 2025, then soared by 1879.23% to $113.5 billion in 2026.
• Business Quant data shows PFE's Total Non-Current Liabilities at $113.5 billion in Q1 2026, $5.7 billion in Q4 2025, and $102.0 billion in Q3 2025.